Pre-competitive consortia may be the favoured collaborative model for emergent, high risk areas or those of general relevance to the pharma sector but where the scope and or costs are too broad / high for a single organisation alone.
NGM Open Innovation are already partners within a number of consortia including: Innovative Medicines Initiative (IMI) Pharmacog, European Prevention of Alzhemier’s Dementia Consortium (EPAD) and the Dementia Consortium (below).
The Dementia Consortium is a collaborative alliance established to accelerate the development of therapeutics for dementia. This exciting project brings together the charity Alzheimer’s Research UK with MRC Technology, and pharmaceutical companies, Eisai and Lilly. It provides funding, expertise and resources to support novel targets and the development of therapeutics for dementia (including Alzheimer’s disease, dementia with Lewy bodies, tauopathies, vascular dementia, frontotemporal dementia and neurodegeneration-associated cognitive deficits).
The Consortium has put together a fund of £3 million to support the best academic research from both the UK and the rest of the world. Funding will be allocated to drug discovery projects (typically 2-3 years in duration) on targets to support target validation and explore the tractability of the target for drug discovery in collaboration with the Consortium members. Work will take place both within academia and at the MRC Technology’s dedicated small molecule and antibody drug discovery laboratories. Applicants and members of the Consortium will help progress successful projects from laboratories towards the clinic, with an ultimate goal of seeing new therapies delivered to patients.
If you are interested applying to the dementia consortium please visit http://www.dementiaconsortium.org/ .
For general enquiries about Eisai's participation in consortia please email email@example.com .